Recent

% | $
Quotes you view appear here for quick access.

Celldex Therapeutics, Inc. Message Board

novochris 2 posts  |  Last Activity: Feb 29, 2016 6:13 PM Member since: Jul 18, 2003
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • novochris novochris Feb 29, 2016 6:13 PM Flag

    Checking your facts via Google "......BMY would acquire MEDX and its antibody-based therapeutics platform for $2.4 billion. No matter how you slice it, this deal is a rich one, offering MEDX shareholders a 90% premium to the stock’s prior-day price and a price to revenue multiple of 47.1x.....The company’s current product pipeline includes ipilimumab, a Phase III clinical trial product in development with BMY for the treatment of metastatic melanoma and other cancers. MEDX also has numerous Phase II clinical trial products; one of MEDX’s partners is AstraZeneca (NYSE: AZN), which acquired the partnership when it bought MedImmune in 2007 for $15.2 billion. ...."

    Thus, assuming CLDX & MEDX equal pipelines, etc. then $2.4 B would be 3.6x higher than CLDX current market cap of $671 MM (or $7 share x 3.6 = $25 share price).

    .... Given CLDX's phase III trial products, I expect a much CLDX share price later this year. However, if you are current about a near term buyout then after having added even more shares today will have a very nice profit.

    Good luck CLDX longs (and especially former MEDX longs). Cheers

    Sentiment: Buy

  • BMY's Opdivo is the same immunotherapy science techonology as CLDX (as BMY purchased from MEDX) ... see article below. This is why I am still holding and recently purchased more CLDX.

    Good luck longs.

    Bristol-Myers shares could rise 25 pct on cancer drug-Barron's
    Reuters
    7 hours ago
    Related Stories

    NEW YORK, Feb 14 (Reuters) - Shares of Bristol-Myers Squibb could rise 25 percent within a year because of its cancer-fighting drug Opdivo, which some analysts see generating $8 billion to $9 billion in annual sales in five years, Barron's said in its latest edition.

    The drug's success in thwarting a number of cancers, including lung, melanoma, renal cell carcinoma, and head and neck, provides a major opportunity for Bristol-Myers, the publication said.

    Bristol-Myers holds an 80 percent share of the fledgling immuno-oncology market, and even as competition increases with treatments, the company is expected to retain a 50 percent to 60 percent share, Barron's said.

    Bristol-Myers in late January forecast 2016 earnings that would represent a gain of almost 20 percent over last year, which would make the company the pharmaceutical industry's earnings-growth pacesetter, Reuters reported at the time.

    Bristol-Myers shares could rise 25 percent

    Sentiment: Hold

CLDX
4.15+0.15(+3.75%)May 2 4:00 PMEDT